Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-14 | John H. Johnson, Director (64) Mr. Johnson has served as a member of our Board of Directors since July 2021. ... Messrs. Johnson (Chairman), and Levine and Ms. Wendell and Dr. Gold are members of the Audit Committee. ... Mr. Johnson currently serves as Chairman of the Audit Committee. |
| 2023-07-07 | None |
| 2024-04-24 | John H. Johnson has served as a member of our Board of Directors since July 2021. Mr. Johnson currently serves as Chief Executive Officer and Board Director of Reaction Biology. Mr. Johnson currently on the Board of Directors of Xeris and Verastem. Mr. Johnson’s qualifications include considerable leadership experience and specific knowledge of the healthcare industry. |
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-28 | He earned his B.S. from the East Stroudsburg University of Pennsylvania. |
| 2016-04-28 | He earned his B.S. from the East Stroudsburg University of Pennsylvania. We believe that Mr. Johnson’s qualifications to serve as a director of our company include his extensive experience as an executive in the biotechnology industry and his prior service as a senior-level executive in mature biotechnology companies. |
| 2016-11-02 | John H. Johnson includes 27,609 shares of Common Stock issuable upon exercise of options exercisable within 60 days of October 18, 2016. |
| 2017-04-27 | He earned his B.S. from the East Stroudsburg University of Pennsylvania. We believe that Mr. Johnson’s qualifications to serve as a director of the Company include his extensive experience as an executive in the biotechnology industry and his prior service as a senior-level executive in mature biotechnology companies. |
| 2018-04-26 | He earned his B.S. from the East Stroudsburg University of Pennsylvania. We believe that Mr. Johnson’s qualifications to serve as a director of the Company include his extensive experience as an executive in the biotechnology industry and his prior service as a senior-level executive in mature biotechnology companies. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22